Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
8-Chloro-Adenosine and Venetoclax in Relapsed/Refractory AML
NCT05263284Phase 1Suspended
- Sponsor
- City of Hope
- Start
- Oct 2022
- Primary completion
- Jan 2029
- Modality
- Orthosteric Ligands, Metabolically Activated Prodrugs
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of 8-chloroadenosine in acute myeloid leukemia (AML), sponsored by City of Hope. Primary endpoints: Incidence of adverse events at 1 year and Dose limiting toxicity at 4 weeks. Started Oct 2022; status: suspended.
02
Drugs
8-chloroadenosine
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on NCT05263284.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05263284.